Inogen Inc. INGN

What this company does

Inogen, Inc. develops, manufactures, and markets respiratory health products, including portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients with chronic respiratory conditions, and the Simeox product for airway clearance treatment. It also distributes the Inogen Voxi 5 stationary oxygen concentrator and the Aurora continuous positive airway pressure masks in the United States. Of the $209.8 million of its 2025 revenue derived from the United States, approximately 45.1% represented sales to home medical equipment providers, distributors and resellers, 29.5% represented direct-to-consumer sales, and 25.4% represented direct-to-consumer rentals. Approximately 39.8% of its total revenue came from outside the United States in 2025, and it has sold its products in a total of 70 countries outside the United States through distributors or directly to large house accounts, including gas companies and home oxygen providers. As of December 31, 2025, it had 753 full and part-time employees worldwide, consisting of 333 in sales, marketing, clinical, and client services, 178 in operations, manufacturing, quality assurance, manufacturing engineering, and repair, 200 in general administration, and 42 in research and development. As of December 31, 2025, it had 25 pending patent applications and 96 issued patents relating to the design and construction of its respiratory devices. It manufactures its oxygen concentrators in a leased building in Plano, Texas, maintains a design facility in Goleta, California, and manufactures the Simeox device in a leased facility in Montpelier, France. It was incorporated in Delaware on November 27, 2001, and it completed an initial public offering of common stock on February 14, 2014, beginning trading on the Nasdaq Global Select Market under the ticker symbol INGN.

Written from the business description in Inogen Inc's annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.